Drug safety evaluation of alemtuzumab for multiple sclerosis

Expert Opinion on Drug Safety

Volumn 13, Issue 8, 2014, Pages 1115-1124

  Willis, Mark ^a   Robertson, Neil P ^a  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Alemtuzumab; Autoimmune disease; Multiple sclerosis; Novel therapeutics

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; ANTIHISTAMINIC AGENT; ANTIPYRETIC AGENT; BETA1A INTERFERON; COMPLEMENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; METHYLPREDNISOLONE; PREDNISOLONE; RITUXIMAB; STEROID; MONOCLONAL ANTIBODY;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE THYROIDITIS; BASAL CELL CARCINOMA; BREAST CANCER; BURKITT LYMPHOMA; CENTRAL NERVOUS SYSTEM INFECTION; COLON CANCER; DISABILITY; DOSE RESPONSE; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; FEVER; GINGIVITIS; GLOMERULONEPHRITIS; GOODPASTURE SYNDROME; GRAVES DISEASE; HEADACHE; HEMOLYTIC ANEMIA; HERPES VIRUS INFECTION; HUMAN; HYPERTHYROIDISM; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE SYSTEM; INFECTION; INFLUENZA; INFUSION RELATED REACTION; LISTERIOSIS; LOW DRUG DOSE; LYMPHOCYTE; LYMPHOCYTOPENIA; MELANOMA; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NEUTROPENIA; NONHUMAN; PATIENT COUNSELING; PATIENT MONITORING; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PYOGENIC GRANULOMA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECURRENCE RISK; RHINOPHARYNGITIS; RIGOR; RISK BENEFIT ANALYSIS; SINUSITIS; THYROID CANCER; THYROID DISEASE; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; UTERINE CERVIX CANCER; METABOLISM; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); TIME;

ANTIBODIES, MONOCLONAL, HUMANIZED; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; LYMPHOCYTES; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PATIENT SELECTION; TIME FACTORS;

EID: 84904510075     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2014.928691     Document Type: Article

References (61)

1. Hafler D, Compston A, Sawcer S, et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007;357(9):851-62
2. Zafranskaya M, Oschmann P, Engel R, et al. Interferon-beta therapy reduces CD4+ and CD8+ T-cell reactivity in multiple sclerosis. Immunology 2007;121(1):29-39
3. Neuhaus O, Farina C, Yassouridis A, et al. Multiple sclerosis: Comparison of copolymer-1-reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc Natl Acad Sci USA 2000;97(13):7452-7
4. Johnson TA, Lapierre Y, Bar-Or A, Antel JP. Distinct properties of circulating CD8+ T cells in FTY720-Treated patients with multiple sclerosis. Arch Neurol 2010;67(12):1449-55
5. Available from: Http://news.genzyme. com/press-release/european- commissionapproves-genzymes-multiple-sclerosistreatment-lemtrada-Alemtuzumab
6. Available from: Http://news.genzyme. com/press-release/genzymes- lemtradaapproved-Australia-Treatment-multiplesclerosis
7. Available from: Http://news.genzyme. com/press-release/genzymes- lemtradaapproved-canada-Treatment-multiplesclerosis
8. Available from: Http://news.genzyme. com/press-release/genzymes- lemtradaapproved-mexico-Treatment-multiplesclerosis
9. Available from: Http://news.genzyme. com/press-release/genzymes- lemtradaapproved-brazil-Treatment-multiplesclerosis
10. Coles AJ, Compston DA, Selmaj KW, et al. Alemtuzumab versus interferon beta-1a in early multiple sclerosis. N Engl J Med 2008;359(17):1786-801
11. Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after diseasemodifying therapy: A randomised controlled phase 3 trial. Lancet 2012;380(9856):1829-39
12. Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: A randomised controlled phase 3 trial. Lancet 2012;380(9856):1819-28
13. Hale G. The CD52 antigen and development of the CAMPATH antibodies. Cytotherapy 2001;3(3):137-43
14. Rao SP, Sancho J, Campos-Rivera J, et al. Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis. PLoS One 2012;7(6):e39416
15. Hale G, Rye PD, Warford A, et al. The glycosylphosphatidylinositol- Anchored lymphocyte antigen CDw52 is associated with the epididymal maturation of human spermatozoa. J Reprod Immunol 1993;23(2):189-205
16. Klotz L, Meuth SG, Wiendl H. Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab. Clin Immunol 2012;142(1):25-30
17. Rowan WC, Hale G, Tite JP, Brett SJ. Cross-linking of the CAMPATH-1 antigen (CD52) triggers activation of normal human T lymphocytes. Int immunol 1995;7(1):69-77
18. Watanabe T, Masuyama J, Sohma Y, et al. CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells. Clin Immunol 2006;120(3):247-59
19. Cheetham G, Hale G. Crystal structures of a rat anti-CD52 (CAMPATH-1) therapeutic antibody Fab fragment and its humanized counterpart. J Mol Biol 1998;284(1):85-99
20. Coles A, Deans J, Compston A. Campath-1H treatment of multiple sclerosis: Lessons from the bedside for the bench. Clin neurol neurosurg 2004;106(3):270-4
21. Lemtrada (alemtuzumab). Summary of Product Characteristics. Genzyme Therapeutics Ltd; 2013
22. Lemtrada (alemtuzumab). Product Information. Sanofi-Aventis Australia Pty Ltd; 2014
23. Fox E, Arnold DL, Cohen J, et al. Durable efficacy of alemtuzumab in relapsing-remitting multiple sclerosis patients who participated in the CAREMS studies: Three-year follow-up. Neurology 2013;80(Meeting Abstracts 1):S41.001
24. Rebello P, Cwynarski K, Varughese M, et al. Pharmacokinetics of CAMPATH-1H in BMT patients. Cytotherapy 2001;3(4):261-7
25. Somerfield J, Hill-Cawthorne GA, Lin A, et al. A novel strategy to reduce the immunogenicity of biological therapies. J Immunol 2010;185(1):763-81
26. Elter T, Molnar I, Kuhlmann J, et al. Pharmacokinetics of alemtuzumab and the relevance in clinical practice. Leuk lymphoma 2008;49(12):2256-62
27. Coles AJ. Alemtuzumab treatment of multiple sclerosis. Semin Neurol 2013;33(1):66-73
28. Hu Y, Turner MJ, Shields J, et al. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology 2009;128(2):260-70
29. Fox EJ. Alemtuzumab in the treatment of relapsing-remitting multiple sclerosis. Expert Rev Neurother 2010;10(12):1789-97
30. Cossburn MD, Harding K, Ingram G, et al. Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis. Neurology 2013;80(1):55-61
31. Hill-Cawthorne GA, Button T, Tuohy O, et al. Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. J neurol neurosurg psychiatry 2012;83(3):298-304
32. Thompson SAJ, Jones JL, Cox AL, et al. B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. J clin Immunol 2010;30(1):99-105
33. Cox AL, Thompson SAJ, Jones JL, et al. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur J Immunol 2005;35(11):3332-42
34. Zhang X, Tao Y, Chopra M, et al. Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis. J Immunol 2013;191(12):5867-74
35. Havari E, Turner MJ, Campos-Rivera J, et al. Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro. Immunology 2014;141(1):123-31
36. Moreau T, Thorpe J, Miller D, et al. Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet 1994;344(8918):298-301
37. Coles AJ, Wing MG, Molyneux P, et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999;46(3):296-304
38. Coles AJ, Cox A, Le Page E, et al. The window of therapeutic opportunity in multiple sclerosis: Evidence from monoclonal antibody therapy. J Neurol 2006;253(1):98-108
39. Hirst CL, Pace A, Pickersgill TP, et al. Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis. J Neurol 2008;255(2):231-8
40. Fox EJ, Sullivan HC, Gazda SK, et al. A single-Arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosis. Eur J Neurol 2012;19(2):307-11
41. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann neurol 2001;50(1):121-7
42. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983;33(11):1444-52
43. Coles AJ, Fox E, Vladic A, et al. Alemtuzumab more effective than interferon beta-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology 2012;78(14):1069-78
44. Coles AJ, Fox E, Vladic A, et al. Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: Post-hoc and subset analyses of clinical efficacy outcomes. Lancet neurol 2011;10(4):338-48
45. Jones JL, Anderson JM, Phuah C-L, et al. Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. Brain 2010;133(Pt 8):2232-47
46. Moreau T, Coles A, Wing M, et al. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 1996;119(Pt 1):225-37
47. Colesa J, Wing M, Smith S, et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 1999;354(9191):1691-5
48. Cossburn M, Pace A, Jones J, et al. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology 2011;77(6):573-9
49. Daniels GH, Vladic A, Brinar V, et al. Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis. J Clin endocrinol metab 2014;99(1):80
50. Jones JL, Thompson SAJ, Loh P, et al. Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation. Proc Natl Acad Sci USA 2013;110(50):20200-5
51. Clatworthy MR Wallin EF, Jayne DR. Anti-glomerular basement membrane disease after alemtuzumab. N Engl J Med 2008;359(7):768-9
52. Lemtrada (alemtuzumab). Product Monograph. Genzyme; Canada: 2013
53. Jones JL, Phuah C, Cox AL, et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest 2009;119(7):2052-61
54. Turner MJ, Lamorte MJ, Chretien N, et al. Immune status following alemtuzumab treatment in human CD52 transgenic mice. J neuroimmunol 2013;261(1-2):29-36
55. McCarthy CL, Tuohy O, Compston DAS, et al. Immune competence after alemtuzumab treatment of multiple sclerosis. Neurology 2013;81(10):872-6
56. Isidoro L, Pires P, Rito L, et al. Progressive multifocal leukoencephalopathy in a patient with chronic lymphocytic leukaemia treated with alemtuzumab. BMJ Case Rep 2014;2014:2013-15
57. Keene DL, Legare C, Taylor E, et al. Monoclonal antibodies and progressive multifocal leukoencephalopathy. Can J Neurol Sci 2011;38(4):565-71
58. Pace AA, Zajicek JP. Melanoma following treatment with alemtuzumab for multiple sclerosis. Eur J Neurol 2009;16(4):e70-1
59. Available from: Http://guidance.nice.org. uk/TAG/339/Consultation/ DraftGuidance
60. Coles AJ, Compston A. Product licences for alemtuzumab and multiple sclerosis. Lancet 2014;383(9920):867-8
61. Costelloe L, Jones J, Coles A. Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis. Expert Rev Neurother 2012;12(3):335-41